This morning Angle reported initial results from its two lead clinical trials with Parsortix, a liquid biopsy system. The two studies ran in parallel in Europe (ANG-001) and the US (ANG-003) and explored Parsortix’s efficacy in triaging women with ovarian masses before surgery ie looking at whether the tumour is benign or malignant to estimate the extent of the necessary surgery. Both studies recruited 200 patients each and reported sensitivity was up to 95%, while specificity was much
05 Jul 2017
Milestone in ovarian cancer application
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Milestone in ovarian cancer application
ANGLE plc (AGL:LON) | 14.8 -0.1 (-4.8%) | Mkt Cap: 38.4m
- Published:
05 Jul 2017 -
Author:
Dr Jonas Peciulis -
Pages:
2
This morning Angle reported initial results from its two lead clinical trials with Parsortix, a liquid biopsy system. The two studies ran in parallel in Europe (ANG-001) and the US (ANG-003) and explored Parsortix’s efficacy in triaging women with ovarian masses before surgery ie looking at whether the tumour is benign or malignant to estimate the extent of the necessary surgery. Both studies recruited 200 patients each and reported sensitivity was up to 95%, while specificity was much